Source: Pharmacogenomics and Personalized Medicine. Unidades: FMRP, FM
Subjects: SEQUENCIAMENTO GENÉTICO, NEOPLASIAS PULMONARES, POLIMORFISMO
ABNT
MACHADO-RUGOLO, Juliana et al. Relevance of PD-L1 non-coding polymorphisms on the prognosis of a genetically admixed NSCLC cohort. Pharmacogenomics and Personalized Medicine, v. 14, p. 239-252, 2021Tradução . . Disponível em: https://doi.org/10.2147/PGPM.S286717. Acesso em: 26 jun. 2025.APA
Machado-Rugolo, J., Prieto, T. G., Fabro, A. T., Cuentas, E. R. P., Sá, V. K. de, Baldavira, C. M., et al. (2021). Relevance of PD-L1 non-coding polymorphisms on the prognosis of a genetically admixed NSCLC cohort. Pharmacogenomics and Personalized Medicine, 14, 239-252. doi:10.2147/PGPM.S286717NLM
Machado-Rugolo J, Prieto TG, Fabro AT, Cuentas ERP, Sá VK de, Baldavira CM, Rainho CA, Castelli E da C, Farhat C, Takagaki TY, Nagai MA, Capelozzi VL. Relevance of PD-L1 non-coding polymorphisms on the prognosis of a genetically admixed NSCLC cohort [Internet]. Pharmacogenomics and Personalized Medicine. 2021 ; 14 239-252.[citado 2025 jun. 26 ] Available from: https://doi.org/10.2147/PGPM.S286717Vancouver
Machado-Rugolo J, Prieto TG, Fabro AT, Cuentas ERP, Sá VK de, Baldavira CM, Rainho CA, Castelli E da C, Farhat C, Takagaki TY, Nagai MA, Capelozzi VL. Relevance of PD-L1 non-coding polymorphisms on the prognosis of a genetically admixed NSCLC cohort [Internet]. Pharmacogenomics and Personalized Medicine. 2021 ; 14 239-252.[citado 2025 jun. 26 ] Available from: https://doi.org/10.2147/PGPM.S286717